Enterome to Present at Upcoming Conferences
News provided by
Share this article
PARIS, April 7, 2021 /PRNewswire/
ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that Pierre Bélichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following conferences:
European Biotech Investor Days: April 7-8
Jefferies Microbiome-based therapeutics Summit: April 22
Jefferies Virtual Healthcare Conference: June 1-3
Enterome s CBO, Anne Dagallier, will participate and take part in 1-on-1 meetings with potential business partners at the following conferences:
Henkel Management Board welcomes Wolfgang König as Executive Vice President Beauty Care
news.europawire.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news.europawire.eu Daily Mail and Mail on Sunday newspapers.
Johnson and Johnson deny vaccine will be available privately in Switzerland
thelocal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelocal.com Daily Mail and Mail on Sunday newspapers.
Published: Mar 12, 2021
Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE)
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19, at its facility near Houston, Texas.
“Manufacturing capacity for COVID-19 vaccines has been severely constrained, and this limitation has presented considerable challenges for vaccine developers,” said Dr. Vyjayanthi Krishnan, Ph.D., Vice President of Product Development for Altimmune. “By expanding our Lonza collaboration and commissioning our own d